Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 88

1.

Synovial tissue research: a state-of-the-art review.

Orr C, Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Le Goff B, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Thurlings R, Fonseca JE, Veale DJ.

Nat Rev Rheumatol. 2017 Aug;13(8):463-475. doi: 10.1038/nrrheum.2017.115. Epub 2017 Jul 13. Review.

PMID:
28701760
2.

Biologics registers in RA: methodological aspects, current role and future applications.

Nikiphorou E, Buch MH, Hyrich KL.

Nat Rev Rheumatol. 2017 Aug;13(8):503-510. doi: 10.1038/nrrheum.2017.81. Epub 2017 Jun 1. Review.

PMID:
28569267
3.

Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritis.

Horton SC, Tan AL, Wakefield RJ, Freeston JE, Buch MH, Emery P.

RMD Open. 2017 Mar 30;3(1):e000394. doi: 10.1136/rmdopen-2016-000394. eCollection 2017.

4.

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).

Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2017 Jul;76(7):1207-1218. doi: 10.1136/annrheumdis-2016-210503. Epub 2017 Feb 10.

5.

Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis.

Bissell LA, Anderson M, Burgess M, Chakravarty K, Coghlan G, Dumitru RB, Graham L, Ong V, Pauling JD, Plein S, Schlosshan D, Woolfson P, Buch MH.

Rheumatology (Oxford). 2017 Jun 1;56(6):912-921. doi: 10.1093/rheumatology/kew488.

PMID:
28160468
6.

Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study.

Buch MH, Hensor EM, Rakieh C, Freeston JE, Middleton E, Horton S, Das S, Peterfy C, Tan AL, Wakefield RJ, Emery P.

Rheumatology (Oxford). 2017 Jan;56(1):58-67. doi: 10.1093/rheumatology/kew357. Epub 2016 Oct 22.

PMID:
28028155
7.

Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group.

Bissell LA, Md Yusof MY, Buch MH.

Rheumatology (Oxford). 2017 Jun 1;56(6):882-895. doi: 10.1093/rheumatology/kew364. Review.

PMID:
27940590
8.

The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be.

Fent GJ, Greenwood JP, Plein S, Buch MH.

Ann Rheum Dis. 2017 Jul;76(7):1169-1175. doi: 10.1136/annrheumdis-2016-209744. Epub 2016 Nov 28. Review.

PMID:
27895040
9.

Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?

Abignano G, Bissell LA, Emery P, Del Galdo F, Buch MH.

Rheumatology (Oxford). 2016 Dec;55(12):2273-2275. Epub 2016 Oct 15. No abstract available.

PMID:
27744357
10.

Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study.

Bissell LA, Hensor EM, Kozera L, Mackie SL, Burska AN, Nam JL, Keen H, Villeneuve E, Donica H, Buch MH, Conaghan PG, Andrews J, Emery P, Morgan AW.

Rheumatology (Oxford). 2016 Dec;55(12):2181-2190. Epub 2016 Sep 16.

PMID:
27638812
11.

The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.

Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):69-76. Epub 2016 Aug 3.

12.

Absence of Scleroderma pattern at nail fold capillaroscopy valuable in the exclusion of Scleroderma in unselected patients with Raynaud's Phenomenon.

Bissell LA, Abignano G, Emery P, Del Galdo F, Buch MH.

BMC Musculoskelet Disord. 2016 Aug 15;17(1):342. doi: 10.1186/s12891-016-1206-5.

13.

BSR and BHPR guideline for the treatment of systemic sclerosis.

Denton CP, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K, Fligelstone K, Gompels LL, Griffiths B, Herrick AL, Pang J, Parker L, Redmond A, van Laar J, Warburton L, Ong VH; BSR and BHPR Standards, Guidelines and Audit Working Group.

Rheumatology (Oxford). 2016 Oct;55(10):1906-10. doi: 10.1093/rheumatology/kew224. Epub 2016 Jun 9. Review. No abstract available.

PMID:
27284161
14.

Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy.

Horton SC, Tan AL, Freeston JE, Wakefield RJ, Buch MH, Emery P.

Rheumatology (Oxford). 2016 Jul;55(7):1177-87. doi: 10.1093/rheumatology/kew037. Epub 2016 Mar 19.

PMID:
26998766
15.

A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA).

Dumitru RB, Horton S, Hodgson R, Wakefield RJ, Hensor EM, Emery P, Buch MH.

BMC Musculoskelet Disord. 2016 Feb 5;17:61. doi: 10.1186/s12891-016-0915-0.

16.

Structural and Functional Analysis of Murine Polyomavirus Capsid Proteins Establish the Determinants of Ligand Recognition and Pathogenicity.

Buch MH, Liaci AM, O'Hara SD, Garcea RL, Neu U, Stehle T.

PLoS Pathog. 2015 Oct 16;11(10):e1005104. doi: 10.1371/journal.ppat.1005104. eCollection 2015 Oct.

17.

B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.

Md Yusof MY, Vital EM, Buch MH.

Curr Rheumatol Rep. 2015 Oct;17(10):65. doi: 10.1007/s11926-015-0539-7. Review.

PMID:
26290110
18.

A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial.

Chaudhry IB, Husain N, ur Rahman R, Husain MO, Hamirani MM, Kazmi A, Baig S, Haddad PM, Buch MH, Qureshi I, Mehmood N, Kiran T, Fu B, Afsar S, Deakin B.

Trials. 2015 Jan 7;16:9. doi: 10.1186/1745-6215-16-9.

19.

The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.

Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, Fernandez C, Gray JC, Hartley S, Hulme C, Keenan AM, McCabe C, Redmond A, Reynolds C, Scott D, Sharples LD, Pavitt S, Buch MH.

BMC Musculoskelet Disord. 2014 Dec 23;15:452. doi: 10.1186/1471-2474-15-452.

20.

Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA): study protocol for a randomized controlled trial.

Erhayiem B, Pavitt S, Baxter P, Andrews J, Greenwood JP, Buch MH, Plein S.

Trials. 2014 Nov 8;15:436. doi: 10.1186/1745-6215-15-436.

Supplemental Content

Support Center